In contrast, other antidiabetic treatment has shown beneficial action on this issue since it recently was demonstrated that Sodium-Glucose Co-transporter-2 (SGLT-2) inhibitors reduced the risk of ISR-driven MACE in subjects with T2D in an observational study; [21] a finding that has to be confirmed in a randomized clinical trial. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.